Clinical trial
Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory…
NCT00274963 · German CLL Study Group, Other · Completed
Key facts
| NCT number | NCT00274963 |
|---|---|
| Title | Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia |
| Official title | Treatment of Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL) WITH Bendamustine / Mitoxantrone (BM) |
| Lead sponsor | German CLL Study Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | bendamustine hydrochloride, mitoxantrone hydrochloride |
| Enrollment | 60 |
| Start date | Oct 1, 2004 |
| Primary completion | Nov 1, 2007 |
| Completion | Oct 1, 2009 |
| First posted | Jan 11, 2006 |
| Last update posted | May 11, 2018 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: